and @edgck, If I can male a suggestion, review all of VRS37 posts carefully. This person is an ill informed person who just posts stuff with no clinical correlation
1) Rituximab as a drug has been used in most of these rare conditions when standard lines of treatment have failed or show no improvement. If you do a quick search on pubmed for rituximab in FSGS you will see that there are calls for a randomised controlled study (of which none have been done yet that I am aware of, happy to be corrected). So as such, clinicians are using it in cases to either buy time prior to a transplant or using it in post transplant patients.
2) From the above statement, what DXB are trying to achieve is a first of its kind in the treatment for FSGS. Once this commercialises, it would have been a drug that has been studied in all phase trials and shown to have a beneficial effect, unlike rituximab which has no randomised trials.
if rituximab is a cheaper option, its only observational. There would have to be a proper study done to compare the DXB with Rituximab to show that efficacy is same/better/worse from a price perspective.
So from the box that VRS37 put up, it is only a matter of time before that flowchart is revised once Dimerix hits the market.
DYOR
- Forums
- ASX - By Stock
- Ann: Investor Presentation
and @edgck, If I can male a suggestion, review all of VRS37...
-
- There are more pages in this discussion • 74 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
|
|||||
Last
55.5¢ |
Change
-0.015(2.63%) |
Mkt cap ! $305.1M |
Open | High | Low | Value | Volume |
56.0¢ | 58.5¢ | 54.0¢ | $3.231M | 5.779M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1118 | 55.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
56.5¢ | 239062 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1118 | 0.555 |
3 | 56053 | 0.550 |
6 | 111652 | 0.545 |
15 | 259396 | 0.540 |
4 | 69275 | 0.535 |
Price($) | Vol. | No. |
---|---|---|
0.565 | 239062 | 1 |
0.570 | 95670 | 3 |
0.575 | 33246 | 2 |
0.580 | 11000 | 1 |
0.585 | 74555 | 5 |
Last trade - 16.10pm 19/06/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |
The Watchlist
CC9
CHARIOT CORPORATION LTD
Shanthar Pathmanathan, MD
Shanthar Pathmanathan
MD
Previous Video
Next Video
SPONSORED BY The Market Online